PRQR Strangle Strategy
PRQR (ProQR Therapeutics N.V.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
PRQR (ProQR Therapeutics N.V.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $179.1M, a beta of 0.07 versus the broader market, a 52-week range of 1.33-3.1, average daily share volume of 547K, a public-listing history dating back to 2014, approximately 166 full-time employees. These structural characteristics shape how PRQR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.07 indicates PRQR has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on PRQR?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current PRQR snapshot
As of May 15, 2026, spot at $1.60, ATM IV 25.70%, IV rank 1.58%, expected move 7.37%. The strangle on PRQR below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on PRQR specifically: PRQR IV at 25.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a PRQR strangle, with a market-implied 1-standard-deviation move of approximately 7.37% (roughly $0.12 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PRQR expiries trade a higher absolute premium for lower per-day decay. Position sizing on PRQR should anchor to the underlying notional of $1.60 per share and to the trader's directional view on PRQR stock.
PRQR strangle setup
The PRQR strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PRQR near $1.60, the first option leg uses a $1.68 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PRQR chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PRQR shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.68 | N/A |
| Buy 1 | Put | $1.52 | N/A |
PRQR strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
PRQR strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on PRQR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on PRQR
Strangles on PRQR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PRQR chain.
PRQR thesis for this strangle
The market-implied 1-standard-deviation range for PRQR extends from approximately $1.48 on the downside to $1.72 on the upside. A PRQR long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current PRQR IV rank near 1.58% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PRQR at 25.70%. As a Healthcare name, PRQR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PRQR-specific events.
PRQR strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PRQR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PRQR alongside the broader basket even when PRQR-specific fundamentals are unchanged. Always rebuild the position from current PRQR chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on PRQR?
- A strangle on PRQR is the strangle strategy applied to PRQR (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With PRQR stock trading near $1.60, the strikes shown on this page are snapped to the nearest listed PRQR chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are PRQR strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the PRQR strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 25.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a PRQR strangle?
- The breakeven for the PRQR strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PRQR market-implied 1-standard-deviation expected move is approximately 7.37%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on PRQR?
- Strangles on PRQR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PRQR chain.
- How does current PRQR implied volatility affect this strangle?
- PRQR ATM IV is at 25.70% with IV rank near 1.58%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.